BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round.

波士顿——（商业新闻短讯）——临床阶段生物治疗公司PureTech Health plc（纳斯达克：PRTC，伦敦证券交易所：PRTC）（“PureTech”或“公司”）注意到，其成立的实体Seaport Therapeutics（“Seaport”）是一家生物制药公司，以成熟的战略和团队推进新型神经精神药物，今天宣布结束了一轮2.25亿美元的超额认购B系列融资。

The syndicate was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech also participated.

该财团由全球领先的增长投资者General Atlantic领导，T.Rowe Price Associates，Inc.，Foresite Capital，Invus，Goldman Sachs Alternatives，CPP Investments和其他新投资者建议的基金和账户参与。创始投资者ARCH Venture Partners、Sofinnova Investments、Third Rock Ventures和联合创始人PureTech也参加了会议。

Following the Series B financing, PureTech will hold equity ownership in Seaport of 36.7% on a diluted basis..

在B轮融资之后，PureTech将在稀释的基础上持有海港36.7%的股权。。

The financing brings the total capital raised by Seaport to $325 million since the Company’s launch in April 2024. Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of the Glyph™ technology platform, which has demonstrated clinical proof-of-concept.

自该公司于2024年4月成立以来，此次融资使Seaport筹集的总资本达到3.25亿美元。Seaport将利用收益通过重要的临床里程碑推进其一流和一流药物的临床阶段管道，并进一步提高Glyph™技术平台的能力，该平台已证明了临床概念验证。

The programs in Seaport’s pipeline use the Glyph platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects to advance clinically active drugs that were previously hindered by those limitations..

海港计划中的项目使用Glyph平台，该平台旨在实现和提高口服生物利用度，避免首过代谢，降低肝酶升高或肝毒性以及其他副作用，以推进先前受到这些限制阻碍的临床活性药物。。

Commenting on today’s announcement, Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech and a member of the Seaport Board of Directors, said:

PureTech首席执行官兼海港董事会成员Bharatt Chowrira博士在评论今天的公告时表示：

“We’re very pleased with Seaport's $225 million Series B financing. Led by a syndicate of top-tier investors, this milestone highlights the significant progress we’re making across our portfolio. The strong support from this stellar investor group not only reinforces the value generated by our unique R&D engine but also underscores our commitment to advancing transformative therapies for patients.

“我们对Seaport 2.25亿美元的B系列融资感到非常高兴。在顶级投资者财团的带领下，这一里程碑突显了我们在整个投资组合中取得的重大进展。这一明星投资者群体的大力支持不仅增强了我们独特的研发引擎产生的价值，也突显了我们致力于推动患者的变革性治疗。

As we look ahead to the upcoming data readout for our internal LYT-100 (deupirfenidone) program, we’re excited to continue driving innovation across our portfolio with the goal of delivering impactful treatments that address significant medical needs.”.

当我们展望即将到来的内部LYT-100（deupirfenidone）计划数据读数时，我们很高兴继续推动我们投资组合的创新，目标是提供有效的治疗方法，满足重大的医疗需求。”。

The full text of the announcement from Seaport is as follows:

海港公告全文如下：

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Seaport Therapeutics结束了2.25亿美元超额认购的B轮融资

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors

融资由General Atlantic牵头，T.Rowe Price Associates、Foresite Capital、Invus、Goldman Sachs Alternatives、加拿大养老金计划投资委员会（CPP Investments）以及其他新投资者参与

Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated

创始投资者ARCH Venture Partners、Sofinnova Investments、Third Rock Ventures和PureTech Health也参加了

Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines

收益将支持海港一流和最佳神经精神药物管道中的关键临床里程碑

BOSTON, October 21, 2024 – Seaport Therapeutics (“Seaport”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T.

波士顿，2024年10月21日–Seaport Therapeutics（“Seaport”）是一家临床阶段的生物制药公司，以成熟的策略和团队推进新型神经精神药物，今天宣布结束一轮2.25亿美元超额认购的B系列融资。该财团由全球领先的增长投资者通用大西洋（General Atlantic）牵头，T。

Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also participated..

Rowe Price Associates，Inc.，Forestite Capital，Invus，Goldman Sachs Alternatives，CPP Investments和其他新投资者。创始投资者ARCH Venture Partners、Sofinnova Investments、Third Rock Ventures和联合创始人PureTech Health也参加了。。

The financing brings the total capital raised by Seaport to $325 million since the company’s launch in April 2024. Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of the Glyph™ technology platform, which has demonstrated clinical proof-of-concept..

自该公司于2024年4月成立以来，此次融资使Seaport筹集的总资本达到3.25亿美元。Seaport将利用收益通过重要的临床里程碑推进其一流和一流药物的临床阶段管道，并进一步提高Glyph™技术平台的能力，该平台已证明了临床概念验证。。

“We are grateful to have the partnership of this incredible group of new and existing investors who share our commitment of delivering better medicines for those suffering from depression, anxiety and other neuropsychiatric disorders,” said Daphne Zohar, Founder and CEO of Seaport Therapeutics. “Seaport is advancing novel therapeutics that have proven clinical efficacy but had previously been held back by an issue we can now address with our Glyph platform.

Seaport Therapeutics创始人兼首席执行官达芙妮·佐哈尔（DaphneZohar）表示：“我们非常感谢这群令人难以置信的新投资者和现有投资者的合作，他们与我们一样致力于为患有抑郁症、焦虑症和其他神经精神疾病的患者提供更好的药物。”。“Seaport正在推进新的疗法，这些疗法已被证明具有临床疗效，但之前由于我们现在可以通过Glyph平台解决的问题而受到阻碍。

This financing enables the important clinical work that brings us another step closer to delivering new medicines to make a difference in the lives of patients and their families.”.

这一资金支持了重要的临床工作，使我们离提供新药更近了一步，从而改变了患者及其家人的生活。”。

“We are excited to partner with Daphne Zohar, Steve Paul and the team at Seaport,” said Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic. “We are impressed with the team’s outstanding CNS clinical track record, as well as Seaport’s Glyph platform and innovative pipeline.

“我们很高兴能与Daphne Zohar、Steve Paul和Seaport团队合作，”General Atlantic董事总经理兼生命科学全球负责人BrettZbar医学博士说。“我们对该团队出色的中枢神经系统临床记录，以及Seaport的Glyph平台和创新管道印象深刻。

The approach to clinical development and trial design demonstrates the deep neuropsychiatric expertise around the table, which we believe offers unique advantages that will contribute to Seaport’s success. We look forward to supporting the company’s next phase of development.”.

临床开发和试验设计的方法展示了桌上深厚的神经精神病学专业知识，我们认为这提供了独特的优势，将有助于海港的成功。我们期待着支持公司下一阶段的发展。”。

The programs in Seaport’s pipeline use the Glyph platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects to advance clinically active drugs that were previously hindered by those limitations.

Seaport管道中的项目使用Glyph平台，该平台旨在实现和提高口服生物利用度，避免首过代谢，减少肝酶升高或肝毒性和其他副作用，以推进先前受到这些限制阻碍的临床活性药物。

The most advanced therapeutic candidate in the pipeline is SPT-300, an oral prodrug of allopregnanolone that is being advanced into a Phase 2b study for major depressive disorder with or without anxious distress that has the potential to be registration-enabling. Allopregnanolone is an endogenous neurosteroid with clinically validated rapid anti-depressant and anxiolytic activity, and SPT-300 retains this activity in an oral form..

正在开发的最先进的治疗候选药物是SPT-300，这是一种口服别孕烯醇酮前药，正在进入2b期研究，用于治疗有或没有焦虑困扰的重度抑郁症，有可能进行登记。Allopregnanolone是一种内源性神经甾体，具有临床验证的快速抗抑郁和抗焦虑活性，SPT-300以口服形式保留了这种活性。。

“The development of important new neuropsychiatric medicines is often halted due to poor drug-like properties or unacceptable tolerability, challenges that our Glyph platform can now uniquely address,” said Steve Paul, M.D., Founder and Board Chair at Seaport Therapeutics. “For instance, xanomeline was an effective drug that faced tolerability challenges, but once resolved, led to the FDA approval of Cobenfy™ (formerly KarXT) for schizophrenia.

Seaport Therapeutics创始人兼董事会主席Steve Paul医学博士说：“重要的新型神经精神药物的开发经常因药物性质差或耐受性不可接受而停止，我们的Glyph平台现在可以独特应对这些挑战。”。“例如，xanomeline是一种有效的药物，面临耐受性挑战，但一旦解决，导致FDA批准Cobenfy™（以前称为KarXT）治疗精神分裂症。

With Glyph, we believe each of Seaport’s programs could create similar life-changing value for patients.”.

有了Glyph，我们相信Seaport的每个项目都可以为患者创造类似的改变生活的价值。”。

SPT-320, a novel prodrug of agomelatine being advanced into Phase 1 studies for the treatment of generalized anxiety disorder (GAD), has the potential to be the first new mechanism for GAD in decades. SPT-320 uses Glyph to bypass liver first-pass metabolism and thus has the potential to lower the dose and reduce liver exposure while retaining efficacious systemic exposure of agomelatine that has been validated in multiple clinical studies in GAD.

。SPT-320使用Glyph绕过肝脏首过代谢，因此有可能降低剂量并减少肝脏暴露，同时保留阿戈美拉汀的有效全身暴露，这已在GAD的多项临床研究中得到验证。

The reduction in dose has the potential to eliminate the need for liver function monitoring that has previously held back agomelatine’s development in GAD. SPT-348, a prodrug of a non-hallucinogenic neuroplastogen in development for the treatment of mood and other neuropsychiatric disorders, uses Glyph to create a potential first-in-class treatment.

剂量的减少有可能消除以前阻碍阿戈美拉汀在GAD中发展的肝功能监测的需要。SPT-348是一种非致幻剂神经塑化剂的前药，正在开发中，用于治疗情绪和其他神经精神疾病，它使用Glyph创造了一种潜在的一流治疗方法。

Beyond these programs, Seaport has multiple discovery and preclinical programs underway..

除了这些计划之外，Seaport还正在进行多项发现和临床前计划。。

About the Glyph™ Platform

关于Glyph™平台

Glyph is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity.

Glyph是Seaport的专有技术平台，它使用淋巴系统来实现和增强药物的口服给药。通过Glyph平台，药物像膳食脂肪一样通过肠道淋巴系统被吸收并运输到循环中。Glyph平台有可能广泛应用于许多具有高首过代谢导致低生物利用度和/或副作用（包括肝酶升高或肝毒性）的治疗分子。

Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the company’s pipeline resulting in new intellectual property, including composition of matter.

Seaport根据波特研究小组的开创性研究，从莫纳什大学独家许可了这项技术。Glyph最初在PureTech Health取得了进展，现在在Seaport取得了进展，已被用于为该公司的管道创建治疗候选药物，从而产生了新的知识产权，包括物质的组成。

The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology and the Journal of Controlled Release supporting the Glyph platform’s capabilities. See Glyph in action here..

该小组及其合作者在《自然代谢》、《药理学前沿》和《控制释放杂志》上发表了支持Glyph平台功能的研究。请参见此处使用的图示符。。

About Seaport Therapeutics

关于海港疗法

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform.

Seaport Therapeutics是一家临床阶段的生物制药公司，致力于在高度未满足患者需求的领域开发新型神经精神药物。该公司有一个经过验证的策略，即推进临床验证的机制，该机制以前受到其专有Glyph技术平台克服的局限性的阻碍。

All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders.

其一流和一流药物管道中的所有候选治疗药物均基于Glyph平台，该平台经过独特设计，可实现口服生物利用度，绕过首过代谢，降低肝酶升高或肝毒性和其他副作用。Seaport由一支经验丰富的团队领导，该团队发明并开发了重要的神经精神药物，并由著名科学家，临床医生和关键意见领袖组成的广泛网络指导。

For more information, please visit www.seaporttx.com..

有关更多信息，请访问www.seaporttx.com。。

Ownership Information

所有权信息

PureTech contributed $14.4 million to the Series B financing and now holds equity ownership in Seaport of 36.7 percent on a diluted basis. Additionally, as the founder of Seaport, PureTech has a right to royalty payments on a percentage of net sales of any commercialized product as well as the right under the terms of the license agreement with Seaport to receive milestone payments upon the achievement of certain regulatory approvals and a percentage of sublicense income..

。此外，作为Seaport的创始人，PureTech有权按任何商业化产品净销售额的百分比获得特许权使用费，并有权根据与Seaport的许可协议条款，在获得某些监管批准和一定比例的分许可收入后获得里程碑付款。。

About PureTech Health

关于PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities.

PureTech是一家临床阶段的生物治疗公司，致力于为新型药物注入活力，以改变毁灭性疾病患者的生活。该公司通过其经验丰富的研发团队以及由科学家、临床医生和行业领导者组成的广泛网络，建立了广泛而深入的渠道，这些网络正在内部和通过其成立的实体进行改进。

PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies.

PureTech的研发引擎已经开发出29种治疗药物和候选治疗药物，其中三种已经获得美国食品和药物管理局的批准。PureTech或其成立的实体正在临床开发的各个适应症和阶段推进许多这些计划，包括注册支持研究。

All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points..

PureTech团队最初确定或发现了产生这一候选治疗药物管道的所有底层程序和平台，然后通过关键验证点进行了改进。。

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

有关更多信息，请访问www.puretechhealth.com或通过X（以前的Twitter）@puretechh与我们联系。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to additional milestones or royalties potentially due to PureTech, Seaport’s development plans for its pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders, potential benefits to patients, the anticipated use of proceeds from the Series B financing and Seaport’s and our future prospects, developments and strategies.

本新闻稿包含属于或可能属于《1995年私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中包含的所有与历史事实无关的声明均应视为前瞻性声明，包括但不限于与PureTech可能产生的额外里程碑或版税有关的声明，Seaport治疗抑郁症，焦虑症和其他神经精神疾病的治疗管道的发展计划，对患者的潜在益处，B系列融资和Seaport的预期收益使用以及我们的未来前景，发展和战略。

The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings.

前瞻性陈述基于当前预期，并受到已知和未知风险、不确定性和其他重要因素的影响，这些因素可能导致实际结果、绩效和成就与当前预期存在重大差异，包括但不限于我们提交给SEC的表20-F年度报告和其他监管文件中“风险因素”标题下描述的风险、不确定性和其他重要因素。

These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise..

这些前瞻性陈述基于对公司当前和未来业务战略及其未来运营环境的假设。每个前瞻性声明仅在本新闻稿发布之日起生效。除法律和监管要求外，我们不承担因新信息、未来事件或其他原因而更新或修订这些前瞻性声明的任何义务。。